Gemifloxacin (Gemifloxacin)
Overview of Gemifloxacin
Gemifloxacin belongs to Flouroquinolone, which are used for management of various bacterial infections. It kills a variety of bacteria, and prevent their reproduction and is often used for the treatment of infections all over the body. However, they are not considerably good for the management of viral infections like flu. Gemifloxacin inhibits the synthesis of DNA by inhibiting DNA gyrase and topoisomerase IV is the enzyme which is needed for bacterial growth.
Indication of Gemifloxacin
Gemifloxacin is primarily indicated in conditions like Bacterial infections, Chronic bronchitis, Cold, Lower respiratory tract infections, Pneumonia, Upper respiratory tract infections, and can also be given in adjunctive therapy as an alternative drug of choice in Diarrhoea.
Contraindication of Gemifloxacin
Gemifloxacin is contraindicated in conditions like Hypersensitivity.
Side Effects of Gemifloxacin
The severe or irreversible adverse effects of Gemifloxacin, which give rise to further complications include Jaundice, Jaundice, Seizures, Bleeding, Diarrhea, Tremors.,Gemifloxacin produces potentially life-threatening effects which include QT prolongation. which are responsible for the discontinuation of Gemifloxacin therapy.,The signs and symptoms that are produced after the acute overdosage of Gemifloxacin include Convulsions, Kidney failure, Confusion, Stomach upset, Headache, Delusions.,The symptomatic adverse reactions produced by Gemifloxacin are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Irritability, Diarrhea, Restlessness, Abdominal pain, Rashes, Nausea and vomiting, dizziness.
Precautions of Gemifloxacin
Should be use with caution in patients with epilepsy or history of seizures, pregnant or breastfeeding patients.Gemifloxacin should be stopped at the first sign of a skin rash or any other allergic reaction nad seek for medical doctor. Though rare, serious and seldom fatal allergic reactions have been reported, even after the first dose.